Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf” NK Cell-Based Cancer Treatments Rapidly to Patients

Sorrento Therapeutics, Inc. announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet  in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer cells derived from induced pluripotent stem cells.